Neoantigen-specific CD8+ T-cell responses are NOT the primary determinants of response in dMMR tumors. Instead, clinical benefit is associated with cytotoxic molecules, NKG2D, nonclassical HLAs and butyrophilins, strongly pointing to a role for gamma/delta T cells
https://aacrjournals.org/clincancerres/article-abstract/30/19/4339/748545/The-Innate-Immune-Landscape-of-dMMR-MSI-Cancers